-
The role of bisphosphonates in the treatment and prevention of bone metastases remains incompletely characterized. In the current report, Diel et al detail long-term survival data on patients with known microscopic bone disease more than eight years after adjuvant treatment with clodronate.
-
Thalidomide-rituximab was administered to 25 symptomatic patients (20 previously untreated) with Waldenstrom macroglobulinemia. The overall response rate was 72%, and the median time-to-progression for responders was 38 months.
-
Among patients who undergo screening and are diagnosed with prostate cancer, there is a dichotomy between those who are diagnosed after their initial screening (prevalent cases) and those who have cancer detected after subsequent screenings (incident cases).
-
A new regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel [FLOT]) was tested in a phase II trial in 54 patients with gastric or gastro-esophageal cancer. Response rates were comparable, or perhaps even a little better than those published for other combinations; the toxicity profile appears favorable.
-
-
The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
-
Probiotics are often thought of as concentrated yogurt capsules, most useful for the prevention or treatment of antibiotic-induced diarrhea. Recent evidence, though, is starting to point to a much greater use for the provision of "good bacteria" to the gastrointestinal tract.
-
A well-regarded, standardized extract of Ginkgo biloba does not appear to help prevent development of dementia in seniors with baseline normal or mildly impaired cognitive function. Whether use of ginkgo earlier in life has a primary preventive effect on development of dementia remains to be determined.
-
Healthy middle-aged men and women with normal LDL-cholesterol levels and elevated levels of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) show significant decreases in clinical cardiovascular events when treated with rosuvastatin vs placebo.
